PIK3CA
Most commonly mutated kinase in cancer. Alpelisib targets PIK3CA-mutated HR+/HER2- breast cancer.
No Clinical Trials found for this biomarker.
Most commonly mutated kinase in cancer. Alpelisib targets PIK3CA-mutated HR+/HER2- breast cancer.
No Clinical Trials found for this biomarker.